Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Lipid disorders and atherosclerosis in children" and "Society guideline links: Obesity in adults".)
International
●Endocrine Society (ES): Clinical practice guideline on primary prevention of ASCVD and T2DM in patients at metabolic risk (2019)
●ES: Clinical practice guideline on evaluation and treatment of hypertriglyceridemia (2012)
Canada
●Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): Guideline for the prevention and management of cardiovascular disease in primary care, update (2018)
●Canadian Cardiovascular Society (CCS): Position statement on familial hypercholesterolemia, update (2018)
●CCS: Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult (2016)
United States
●American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA): Guideline for the management of heart failure (2022)
●AHA/American Stroke Association (ASA): Guideline for the prevention of stroke in patients with stroke and transient ischemic attack (2021)
●AHA: Scientific statement on genetic testing for inherited cardiovascular diseases (2020)
●ACC/AHA: Guideline on the primary prevention of cardiovascular disease (2019)
●Choosing Wisely: Don't routinely prescribe lipid-lowering medications in individuals with a limited life expectancy (2013, updated 2019)
●AHA: Scientific statement on atherosclerotic cardiovascular disease in South Asians in the United States – Epidemiology, risk factors, and treatments (2018)
●AHA: Scientific statement on cardiovascular disease and breast cancer – Where these entities intersect (2018)
●AHA/ACC/American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)/American Academy of Physician Assistants (AAPA)/Association of Black Cardiologists (ABC)/American College of Preventive Medicine (ACPM)/American Diabetes Association (ADA)/American Geriatrics Society (AGS)/American Pharmacists Association (APhA)/American Society for Preventive Cardiology (ASPC)/National Lipid Association (NLA)/Preventive Cardiovascular Nurses Association (PCNA): Guideline on the management of blood cholesterol (2018)
●American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE): Guidelines for management of dyslipidemia and prevention of cardiovascular disease (2017)
●ACC: Expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk, focused update (2017)
●AHA: Scientific statement on cardiovascular health in African Americans (2017)
●NLA: Recommendations from an expert panel on the use of PCSK9 inhibitors in adults, update (2017)
•NLA: Recommendations for patient-centered management of dyslipidemia – Part 1 (2015)
•NLA: Recommendations for patient-centered management of dyslipidemia – Part 2 (2015)
●AHA: Scientific statement on contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure (2016)
●Choosing Wisely: Do not routinely order expanded lipid panels (particle sizing, nuclear magnetic resonance) as screening tests for cardiovascular disease (2016)
●US Preventive Services Task Force (USPSTF): Final recommendation statement on lipid disorders in children and adolescents – Screening (2016)
●USPSTF: Final recommendation statement on statin use for the primary prevention of cardiovascular disease in adults – Preventive medication (2016)
●AHA: Scientific statement on the agenda for familial hypercholesterolemia (2015)
●ACC/AHA: 2013 guideline on the assessment of cardiovascular risk (published 2014)
●US Department of Veterans Affairs (VA) and US Department of Defense (DoD): Clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction (2014)
●ACC/AHA: Guideline on lifestyle management to reduce cardiovascular risk (2013)
●ACC/AHA/The Obesity Society (TOS): Guideline for the management of overweight and obesity in adults (2013)
●NLA: Clinical guidance on familial hypercholesterolemia – Screening, diagnosis and management of pediatric and adult patients (2011)
Europe
●European Society of Cardiology (ESC): Guidelines on cardiovascular disease prevention in clinical practice (2021)
●European Atherosclerosis Society (EAS) and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM): Consensus statement on quantifying atherogenic lipoproteins for lipid-lowering strategies (2020)
●ESC/EAS: Guidelines for the management of dyslipidaemias – Lipid modification to reduce cardiovascular risks (2019)
●European Society of Hypertension (ESH) and European Association for the Study of Obesity (EASO): A call for action on obesity and cardiovascular risk – Part A: Mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment (2018)
●ESC/EAS: Consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors – Practical guidance for use in patients at very high cardiovascular risk (2017)
●ESC/EAS: Practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia, update (2017)
●EAS and EFLM: Joint consensus statement on fasting is not routinely required for determination of a lipid profile – Clinical and laboratory implications including flagging at desirable concentration cut-points (2016)
●EAS: Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease (2014)
●EAS: Position paper on homozygous familial hypercholesterolaemia – New insights and guidance for clinicians to improve detection and clinical management (2014)
●EAS: Consensus statement on familial hypercholesterolaemia is underdiagnosed and undertreated in the general population – Guidance for clinicians to prevent coronary heart disease (2013)
●EAS: Consensus statement on the polygenic nature of hypertriglyceridaemia – Implications for definition, diagnosis, and management (2013)
United Kingdom
●National Institute for Health and Care Excellence (NICE): Clinical guideline on familial hypercholesterolaemia – Identification and management (2008, updated 2019)
●Hyperlipidaemia Education and Atherosclerosis Research Trust United Kingdom (HEART UK): Statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom (2016)
●NICE: Clinical guideline on cardiovascular disease – Risk assessment and reduction, including lipid modification (2014, updated 2016)
●NICE: Quality standard on cardiovascular risk assessment and lipid modification (2015)
●NICE: Quality standard on familial hypercholesterolaemia (2013)
Australia-New Zealand
●Cardiac Society of Australia and New Zealand (CSANZ): Position statement for the diagnosis and management of familial hypercholesterolaemia (2016)
●Choosing Wisely Australia: Don't commence therapy for hypertension or hyperlipidaemia without first assessing the absolute risk of a cardiovascular event (2015)
●Choosing Wisely Australia: Do not routinely test and treat hyperlipidemia in those with a limited life expectancy (2015)
●Royal Australian College of General Practitioners (RACGP): Detecting familial hypercholesterolaemia in general practice (2012)
●Practical Implementation Taskforce for the Prevention of Cardiovascular Disease: Evidence-based clinical aid for the prevention of cardiovascular disease (2004)
Japan
●[In Japanese] Choosing Wisely Japan: Drugs for dyslipidemia for elderly people over 75 years old – When necessary and not necessary (2018)
●[In English] Japan Atherosclerosis Society (JAS): 2017 guidelines for diagnosis and treatment of familial hypercholesterolemia (published 2018)
●[In English] JAS: 2017 guidelines for prevention of atherosclerotic cardiovascular diseases (published 2018)
